-
CTOP for μ-Opioid Receptor Research
2026-09-15
CTOP provides a selective pharmacological handle for separating μ-opioid receptor activity from downstream pain-circuit effects. This workflow-focused guide shows how to use the peptide in binding, signaling, and pain-model experiments while avoiding common interpretation and handling errors.
-
Caged Bioluminescent Probe for Immunoproteasome
2026-09-15
The reference study presents a cleavable, bioluminescent activity-based probe designed to selectively report immunoproteasome activity, especially the β5i-containing isoform. Its synthesis and plate-reader workflow provide a practical route for measuring immunoproteasome function in cellular systems and tissue-mimicking conditions while highlighting the remaining gap between assay validation and in vivo application.
-
TerminaTOR Reveals Nuclear mTORC1 Transcription
2026-09-14
The reference study introduces TerminaTOR, a genetically encodable inhibitor that selectively perturbs mTORC1 at defined subcellular locations. By comparing lysosomal and nuclear inhibition, the authors show that nuclear mTORC1 has a distinct role in regulating transcription of CCAAT motif-containing genes rather than merely reproducing canonical lysosomal outputs.
-
4-PBA: Turning ER Stress Into Causal Biology
2026-09-14
4-Phenylbutyric acid is more than a general chemical chaperone: used strategically, it can help translational researchers test whether endoplasmic reticulum stress is causally linked to apoptosis, autophagic cell death, or therapeutic response. A recent liver cancer study illustrates how 4-PBA can convert pathway observations into a mechanistic rescue experiment.
-
MK-571 (L-660,711) Assay Workflows
2026-09-13
MK-571 (L-660,711) supports both leukotriene receptor pharmacology and mechanistic studies of MRP1/ABCC1-dependent drug handling. This guide connects airway inflammation models with macrophage protection assays while highlighting controls that prevent dual-target interpretation errors.
-
(-)-Blebbistatin for Mechanomemory Assays
2026-09-12
Discover how (-)-Blebbistatin can turn mechanomemory experiments into causal tests of actomyosin-dependent YAP signaling. This article connects selective non-muscle myosin II inhibition with intermittent-stress design, cytoskeletal readouts, and practical assay controls.
-
BCECF-AM for Intracellular pH in Secretion Studies
2026-09-12
BCECF-AM converts intracellular pH changes into a quantitative ratiometric signal for live-cell studies of secretion, stress, and compartment function. Its cell entry and esterase activation support workflows in mammalian and plant systems, while practical calibration and troubleshooting guidance helps distinguish cytosolic responses from endomembrane effects.
-
PF-562271 HCl for FAK/Pyk2 Cancer Research
2026-09-11
PF-562271 HCl provides a reversible way to dissect FAK/Pyk2 signaling across tumor-cell, adhesion, migration, and microenvironment assays. This workflow connects precise kinase pharmacology with blood-based CAML phenotyping while clearly separating reference findings from hypothesis-generating applications.
-
Nocodazole: From Microtubules to Translational Insight
2026-09-11
Nocodazole is more than a mitotic arrest reagent. As a reversible microtubule polymerization inhibitor, it can help translational researchers separate cytoskeletal control of endocytic entry, intracellular trafficking, cell-cycle behavior, and anticancer response—provided that reversibility, viability, and pathway-specific controls are built into the study design.
-
Docetaxel Workflows for Chemoresistance Research
2026-09-10
Build reproducible Docetaxel assays that connect microtubule stabilization to mitotic arrest, apoptosis, and multidrug resistance. This practical workflow translates a renal cell carcinoma study into dose-response, transporter, combination, and xenograft-oriented experiments.
-
Gingerenone A Reverses Sunitinib Resistance in RCC
2026-09-10
The reference study identifies gingerenone A as a metabolic intervention that targets LDHA-driven glycolysis and restores sunitinib responsiveness in renal cell carcinoma models. Its combination of target discovery, metabolic rescue experiments, proliferation assays, and in vivo validation supports a mechanistic link between lactate metabolism, HIF-1α signaling, and treatment resistance.
-
AZD2461: Reliable PARP Inhibitor Assay Design
2026-09-09
Learn how AZD2461, SKU A4164, can support more interpretable viability, proliferation, and cytotoxicity assays in breast cancer research. This scenario-based guide connects PARP biology with practical decisions about dosing, solvent handling, controls, data interpretation, and product selection.
-
RNAi Reveals Rab11a-Linked SARS-CoV-2 Release
2026-09-09
Kerr et al. developed an RNA interference screen designed to capture host factors acting across the SARS-CoV-2 replication and reinfection cycle, including late assembly and release events often underrepresented in host-factor studies. The work identifies Rab11a-linked vesicular transport as a conserved proviral pathway and shows that pharmacological CDK9 inhibition with CDKI-73 can block viral release.
-
Toremifene Citrate: From Mechanism to Translation
2026-09-08
A translational perspective on Toremifene Citrate, connecting estrogen receptor biology, experimental design, comparative SERM strategy, and clinically informed research planning.
-
MLN8237 (Alisertib) in Cancer Research
2026-09-08
MLN8237 (Alisertib) gives researchers a selective pharmacological handle on Aurora A, connecting mitotic control with apoptosis, tumor growth inhibition, and immune-metabolic regulation. This workflow-focused guide covers dose design, orthogonal validation, trained-immunity assays, and troubleshooting for more reproducible cancer biology experiments.